Personalis updates on NeXT colorectal cancer detection study

The company states: “Personalis (PSNL) announced new interim analysis results of the VICTORI study showing strong performance of its ultra-sensitive NeXT Personal assay in detecting early signs of residual or recurrent colorectal cancer. The study, led by Dr. Jonathan Loree’s team at BC Cancer in Vancouver, Canada, utilized NeXT Personal to look for small traces of circulating tumor DNA in blood samples from a cohort of 71 patients with resectable Stage I-IV CRC. The data was presented at the American Association for Cancer Research Annual Meeting in Chicago, Illinois by Emma Titmuss at BC Cancer, in an oral presentation titled Detection of post-surgical minimal residual disease in colorectal cancer; preliminary results from the VICTORI study. Key findings presented from the interim analysis for VICTORI: 100% of patients who have recurred were detected as ctDNA positive by NeXT Personal prior to detection on imaging. 100% of patients who have been ctDNA negative throughout the study remain disease-free. 87% of clinical recurrences were detectable within the early “landmark window” 2 to 8 weeks after surgery, with 85% detectable by 4 weeks. 64% of detections within the landmark window were in the ultrasensitive range.”